Interestingly, Lorazepam, a selective GPR68 agonist, increased the expression of IL-6 through GPR68 in human PDAC CAFs and was associated with poor survival outcomes in pancreatic cancer [165]. Here, IL6 is linked to pancreatic neoplasm.